Related Experiment Video

Updated: Jul 12, 2026

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis
06:17

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis

Published on: May 22, 2018

Branched KLVFF tetramers strongly potentiate inhibition of beta-amyloid aggregation

Sidhartha M Chafekar1, Hinke Malda, Maarten Merkx

  • 1Neurogenetics Laboratory, Academic Medical Center, P.O. Box 22660, 1100 DD Amsterdam, The Netherlands.

Chembiochem : a European Journal of Chemical Biology
|September 1, 2007
PubMed

Insights

A novel dendrimer drug effectively inhibits beta-amyloid aggregation in Alzheimer's disease (AD) models. This KLVFF-conjugated dendrimer, K(4), shows potent inhibition and disassembly of toxic Abeta aggregates, offering a promising therapeutic strategy for AD.

Area of Science:

  • Neuroscience
  • Biochemistry
  • Materials Science

Background:

  • Alzheimer's disease (AD) pathogenesis involves beta-amyloid (Abeta) peptide aggregation.
  • The KLVFF amino acid sequence is critical for Abeta aggregation.
  • Developing inhibitors of Abeta aggregation is a key therapeutic strategy for AD.

Purpose of the Study:

  • To investigate the potential of a dendrimer scaffold for multivalent display of the KLVFF peptide.
  • To evaluate the efficacy of a dendrimer-conjugated KLVFF peptide (K(4)) in inhibiting Abeta aggregation compared to monomeric KLVFF (K(1)).
  • To assess the ability of K(4) to disrupt existing Abeta aggregates.

Main Methods:

  • Synthesis of a first-generation dendrimer displaying four KLVFF peptides (K(4)).
  • Comparative analysis of K(4) and monomeric KLVFF (K(1)) on Abeta(1-42) aggregation.
  • Concentration-dependent inhibition assays and assessment of aggregate disassembly.

Main Results:

  • K(4) demonstrated significantly more potent inhibition of Abeta(1-42) aggregation into fibrils than K(1).
  • Inhibition was observed for both low-molecular-weight and protofibrillar Abeta species.
  • K(4) was also found to effectively disassemble pre-formed Abeta aggregates.

Conclusions:

  • Multivalent display of KLVFF peptides on a dendrimer scaffold enhances anti-amyloidogenic activity.
  • Dendrimer-KLVFF conjugates represent a promising therapeutic approach for Alzheimer's disease.
  • This strategy holds potential for both preventing and reversing Abeta aggregation in AD.

More Related Videos

Analysis of β-Amyloid-induced Abnormalities on Fibrin Clot Structure by Spectroscopy and Scanning Electron Microscopy06:27

Analysis of β-Amyloid-induced Abnormalities on Fibrin Clot Structure by Spectroscopy and Scanning Electron Microscopy

Published on: November 30, 2018

Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices04:41

Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices

Published on: July 14, 2010

Related Concept Videos

Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...
Inhibitors of Virion Maturation and Assembly01:19

Inhibitors of Virion Maturation and Assembly

As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...